CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

HP:0002206: Pulmonary fibrosisHPO

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation

Correlated Drug Terms (2)

Name (Synonyms) Correlation
drug524 N-acetylcysteine+ Fuzheng Huayu Tablet Wiki 1.00
drug525 N-acetylcysteine+Placebo Wiki 1.00

Correlated MeSH Terms (2)

Name (Synonyms) Correlation
D005355 Fibrosis NIH 0.71
D011658 Pulmonary Fibrosis NIH 0.58

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 A Randomized, Placebo-Controlled, Multi-Center Study on the Efficacy and Safety of Fuzheng Huayu on Pulmonary Fibrosis Due to 2019-nCoV

Inflammation is the early stage of fibrosis. Serious patients are more likely to develop into pulmonary fibrosis, which affects the recurrence of lung function or even threatens life and health. This study is planned to observe the efficacy and safety of Fuzheng Huayu tablets in the treatment of pulmonary fibrosis after COVID-19.

NCT04279197 Pulmonary Fibrosis Due to 2019-nCoV Drug: N-acetylcysteine+ Fuzheng Huayu Tablet Drug: N-acetylcysteine+Placebo
MeSH:Pulmonary Fibrosis Fibrosis
HPO:Pulmonary fibrosis

Primary Outcomes

Description: Evaluation of Pulmonary fibrosis Improvement. HRCT images are graded from 1 to 6, higher scores mean a worse outcome.

Measure: High-resolution computed tomography (HRCT) score

Time: Week 24

Description: Evaluation of Lung Function Improvement

Measure: Lung function including FVC, FVC as a percentage of projected value and DLco

Time: Week 24

Secondary Outcomes

Description: Times of acute exacerbations during treatment

Measure: Times of acute exacerbation

Time: Week 24

Description: Measured by a 6-minute walking test

Measure: Six-minute walk distance

Time: Week 24

Description: Using the scale revised by British modified Medical Research Council (MMRC) which divided patients into five degrees.Higher scores mean a worse outcome.

Measure: Dyspnea Scores

Time: Week 24

Description: Evaluation of Pulmonary fibrosis Improvement on CT which is calculated by formula.

Measure: Composite physiological index

Time: Week 24

HPO Nodes